Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

Company Performance - Veracyte reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and up from $0.30 per share a year ago, representing an earnings surprise of +41.94% [1] - The company achieved revenues of $130.16 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.06%, compared to $114.43 million in the same quarter last year [2] - Over the last four quarters, Veracyte has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Veracyte shares have declined approximately 36.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Veracyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.33 on revenues of $125.73 million, and for the current fiscal year, it is $1.32 on revenues of $493.72 million [7] - The outlook for the Medical - Instruments industry, where Veracyte operates, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]